Anavex Life Sciences Corp (AVXL)

[falconer66a]

Might Anavex-facilitated Sleep Prevent Alzheimer’s?

Evidence is mounting that alterations to normal sleep patterns affect disease progression, promoting the appearance of ß-amyloid (Aß) and tau aggregates that are progressively deposited in the brains of patients with Alzheimer’s disease (AD).

Presently, the focus of Anavex 2-73 regarding Alzheimer’s disease is to provide useful treatment, in patients suffering with the disease. Well and good.

But, as the statement above indicates, “...alterations to normal sleep patterns affect disease progression, promoting the appearance of ß-amyloid (Aß) and tau aggregates....”

Which, then, of the following might be so? Which does not follow? Why?

1. Beta amyloid and tau protein wastes are prime pathogenic factors in Alzheimer’s

2. Altered, disrupted, or inadequate sleep promotes the appearance of beta amyloid and tau protein wastes.

3. Anavex 2-73 promotes, facilitates, or induces normalized sleep in older humans.

4. Anavex 2-73-induced good sleep patterns restrict or prohibit the appearance of beta amyloid and tau protein wastes.

5. Without beta amyloid and tau protein wastes, Alzheimer’s disease does not occur.

6. Early administration of Anavex 2-73 induces healthful sleep, thereby restricts or prohibits beta amyloid and tau protein waste accumulations; consequently Alzheimer’s disease does not occur.

7. Anavex 2-73 has potential, then, to be an Alzheimer’s prophylactic (preventative), not just a treatment therapy.